Description
Founded in 2016, T1D Fund is a venture capital firm based in Boston, Massachusetts. The firm seeks to invest in biotech and pharma companies developing therapeutics, diagnostics, devices, and vaccines for people living with or at risk of developing type 1 diabetes sectors.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Biolinq | 17-Oct-2022 | Later Stage VC | 00000 | Monitoring Equipment | Clinical Trials - Phase 2 | |
000000000 000000 | 14-Oct-2022 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 2 | |
0000 000000000000 | 01-Jul-2022 | 00000 00000 | Drug Discovery | Generating Revenue | ||
0000 000 | 25-May-2022 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 0000 000000000 00.0 |
00000 | 10-May-2022 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
000000 0000 000000 | 29-Mar-2022 | 00000 00000 | Drug Discovery | Pre-Clinical Trials | 00000 000000 | |
00000000 | 11-Aug-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | |
000000 00000000000 | 04-Aug-2021 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
Kriya | 14-Jul-2021 | Early Stage VC | 00000 | Drug Discovery | Pre-Clinical Trials | |
Abata Therapeutics | 23-Jun-2021 | Early Stage VC | 0000 | Biotechnology | Startup |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Capillary Biomedical | 21-Jul-2022 | Merger/Acquisition | 000.00 |
0000000000000 | 10-Sep-2021 | 000000000000000000 | 0000 |
00000000 000000000 | 14-Jul-2021 | 000000000000000000 | 000 |
0000000000 | 05-Feb-2021 | 000 | 00000 |
00000000 | 08-Jan-2021 | 000 00 00000000 | |
000 0000000 | 30-Oct-2020 | 000 | 000.00 |
0000000 0000000000 | 17-Jul-2020 | 000 | 00000 |
Semma Therapeutics | 10-Oct-2019 | Merger/Acquisition | 00000 |
Provention Bio | 24-Jul-2018 | IPO | 000.00 |
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Katie Ellias | Managing Director & Member of Investment Committee | 0 | 0 | 0 | Boston, MA |
Steven Peter MD | Managing Director & Chairman of Investment Committee | 0 | Boston, MA | ||
Bruce Buckingham MD | Partner & Advisor | Boston, MA | |||
Carmella Evans-Molina Ph.D | Partner & Advisor | Boston, MA | |||
Chantal Mathieu Ph.D | Partner & Advisor | Boston, MA |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Polaris Partners | 3 | 0 | 0 |
![]() |
![]() |
Amgen Ventures | 0 | 0 |
![]() |
![]() |
|
Frazier Healthcare Partners | 0 | 0 |
![]() |
![]() |
|
Genesys Capital | 0 | 0 |
![]() |
![]() |
|
The Invus Group | 0 | 0 | 0 |
![]() |
![]() |